ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND ...

Last year, the FDA placed a partial clinical hold on tolebrutinib phase 3 trials in MS and myasthenia gravis after cases of drug-induced liver injury were observed, with recruitment of new studies ...

The UK regulatory authority has cleared the path for some patients with generalised myasthenia gravis (gMG) to get early access to Argenx' efgartigimod while it reviews the marketing application ...